Pneumococcal conjugate vaccine in adults: Let's see what happens

Human Vaccines & Immunotherapeutics
Peter R Paradiso

Abstract

The recent recommendation for the use of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults 65 y of age and older, provides a new tool for preventing disease in this at-risk population. The conjugate vaccine induces a T-cell dependent response, which distinguishes it from the polysaccharide vaccine and could provide the longer-term protection necessary to have a significant impact in this population.

References

Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
May 3, 2014·Human Vaccines & Immunotherapeutics·Daniel M Musher, Maria C Rodriguez-Barradas
Mar 19, 2015·The New England Journal of Medicine·Marc J M BontenDiederick E Grobbee
Oct 27, 2015·JAMA Internal Medicine·Michael Hochman, Pieter A Cohen
Oct 27, 2015·JAMA Internal Medicine·Anne Schuchat

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

CAPiTA

Related Concepts

Related Papers

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
C N FerreiraC Rufino
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Katherine L O'Brien
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Corinne LevyRobert Cohen
© 2022 Meta ULC. All rights reserved